Abstract
Abstract Ovarian cancer is the leading cause of death from gynecological malignancies. The five-year survival rate of ovarian cancer ranges from 30 to 92%, depending on the severity of the disease. Our laboratory has shown the role of chemokines and chemokines receptors in cancer, including ovarian cancer. In this study, we have shown higher expression of CXCR6, which is the only receptor of chemokine CXCL16, in ovarian cancer cell lines and clinical samples. We have tested the biological significance of CXCR6 and soluble CXCL16 (sCXCL16) using ovarian cancer cell lines in vitro. We show higher migratory and invasive potential of high CXCR6 expressing ovarian cancer cell lines in the response of sCXCL16. Migratory and invasive potential in response to sCXCL16 was significantly inhibited when CXCR6 and CXCL16 interaction was blocked using anti-CXCR6 monoclonal antibody. ADAM10 basal mRNA level was higher in cells with high migratory and invasive potential. Similar to cell lines, higher expression of CXCR6 and CXCL16, as well as ADAM10, was observed in tissue, which showed a positive correlation with tumor stage. These results suggest the clinical and biological significance of CXCR6-CXCL16 axis in the pathogenesis of ovarian cancer. Therefore, therapeutics directed to the CXCR6-CXCL16 axis may provide better therapeutic outcome and overall survival. Citation Format: Hina Mir, Neeraj Kapur, James W. Lillard, Shailesh Singh. Role of CXCL16 and ADAM10 in ovarian cancer pathogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1924.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call